Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

140 ARTÍCULOS , VIENDO DEL 16 AL 30

Concordance and Diagnostic Accuracy of [11C]PIB PET and Cerebrospinal Fluid Biomarkers in a Sample of Patients with Mild Cognitive Impairment and Alzheimer's Disease

Leuzy A, Carter SF, Chiotis K, Almkvist O, Wall A, Nordberg A.

J Alzheimers Dis. 2015;45(4):1077-88. doi: 10.3233/JAD-142952.

A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease

Olazarán J, Gil-de-Gómez L, Rodríguez-Martín A, Valentí-Soler M, Frades-Payo B, Marín-Muñoz J, Antúnez C, Frank-García A, Acedo-Jiménez C, Morlán-Gracia L, Petidier-Torregrossa R, Guisasola MC, Bermejo-Pareja F, Sánchez-Ferro Á, Pérez-Martínez DA, Manzano-Palomo S, Farquhar R, Rábano A, Calero M.

J Alzheimers Dis. 2015;45(4):1157-73. doi: 10.3233/JAD-142925.

Paths to Alzheimer's disease prevention: from modifiable risk factors to biomarker enrichment strategies

Lista S, Dubois B, Hampel H.

J Nutr Health Aging. 2015 Feb;19(2):154-63. doi: 10.1007/s12603-014-0515-3.

Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria

Höglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E.

Clin Chim Acta. 2015 Sep 20;449:3-8. doi: 10.1016/j.cca.2015.01.041. Epub 2015 Feb 7.

Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF

Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N, Nairn AC, Croteau P, Schirm M, Allard R, Lamontagne J, Chelsky D, Hoffmann S, Potter WZ; Alzheimer's Disease Neuroimaging Initiative; Foundation for NIH (FNIH) Biomarkers Consortium CSF Proteomics Project Team.

Proteomics Clin Appl. 2015 Aug;9(7-8):715-31. doi: 10.1002/prca.201400178. Epub 2015 Apr 24.

LEAP: biomarker inference through learning and evaluating association patterns

Jiang X, Neapolitan RE.

Genet Epidemiol. 2015 Mar;39(3):173-84. doi: 10.1002/gepi.21889. Epub 2015 Feb 12.

RNA testing now automated

Kricka LJ, Wilson RB.

Clin Chem. 2015 Apr;61(4):571-2. doi: 10.1373/clinchem.2014.237594. Epub 2015 Feb 18.

The biomarker and therapeutic potential of miRNA in Alzheimer's disease

Bekris LM, Leverenz JB.

Neurodegener Dis Manag. 2015;5(1):61-74. doi: 10.2217/nmt.14.52.

Quantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applications

Bros P, Delatour V, Vialaret J, Lalere B, Barthelemy N, Gabelle A, Lehmann S, Hirtz C.

Clin Chem Lab Med. 2015 Sep 1;53(10):1483-93. doi: 10.1515/cclm-2014-1048.

Circulating Biomarker Panels in Alzheimer's Disease

Zafari S, Backes C, Meese E, Keller A.

Gerontology. 2015;61(6):497-503. doi: 10.1159/000375236. Epub 2015 Feb 25.

Oxidative Stress and Aberrant Cell Cycle in Alzheimer's Disease Lymphocytes: Diagnostic Prospects

Wojsiat J, Prandelli C, Laskowska-Kaszub K, Martín-Requero A, Wojda U.

J Alzheimers Dis. 2015;46(2):329-50. doi: 10.3233/JAD-141977.

Neurotransmitter measures in the cerebrospinal fluid of patients with Alzheimer's disease: a review

Strac DS, Muck-Seler D, Pivac N.

Psychiatr Danub. 2015 Mar;27(1):14-24.

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials

Kim SY, Karlawish J, Berkman BE.

Neurology. 2015 Apr 7;84(14):1488-94. doi: 10.1212/WNL.0000000000001451. Epub 2015 Mar 11.

Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer's Disease

Körtvélyessy P, Gukasjan A, Sweeney-Reed CM, Heinze HJ, Thurner L, Bittner DM.

J Alzheimers Dis. 2015;46(2):375-80. doi: 10.3233/JAD-150069.

[Cerebrospinal fluid markers in early diagnosis of Alzheimer dementia]

Wiltfang J.

Ther Umsch. 2015 Apr;72(4):271-8. doi: 10.1024/0040-5930/a000675.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias